Clinical Trials
22 trialsNCT05181462 2026-05-27
TRIFOUR
Cantargia AB
Phase 1/2 Completed
NCT06841354 2026-05-22
TroFuse-011
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT03606967 2026-05-13
Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT05347134 2026-05-08
SKB264 Injection vs Investigator Selected Regimens to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 3 Active not recruiting
NCT06926868 2026-04-30
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
Bristol-Myers Squibb
Phase 2/3 Recruiting
NCT06027268 2026-04-22
ToPCourT
Wake Forest University Health Sciences
Phase 2 Active not recruiting
NCT07544056 2026-04-22
A Study of BEBT-209 Plus Chemotherapy in Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer
BeBetter Med Inc
Phase 2/3 Not yet recruiting
NCT06382142 2026-04-20
A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer(PANKU-Breast02)
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3 Active not recruiting
NCT06492759 2026-04-17
High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer
Emory University
Phase 2 Recruiting
NCT07533123 2026-04-16
A Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Cancer Who Have Failed Standard of Care
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Phase 3 Recruiting
NCT07528768 2026-04-14
Gemcitabine vs Paclitaxel in Caribbean Women of African Ancestry With Metastatic Triple-Negative Breast Cancer
AntiCancer Research Jamaica
Phase 2 Not yet recruiting
NCT04491942 2026-04-13
Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT05382299 2026-04-06
ASCENT-03
Gilead Sciences
Phase 3 Active not recruiting
NCT04191135 2026-03-03
KEYLYNK-009
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT06449222 2026-02-25
Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy
BioNTech SE
Phase 2 Active not recruiting
NCT06519370 2026-01-22
FDA018-ADC vs Investigator's Choice Chemotherapy to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Phase 3 Active not recruiting
NCT04722978 2025-12-17
Standard Chemotherapy Plus Moxifloxacin as First-line Treatment for Metastatic Triple-negative Breast Cancer
Sun Yat-sen University
Phase 3 Recruiting
NCT03371017 2025-11-12
IMpassion132
Hoffmann-La Roche
Phase 3 Completed
NCT05382286 2025-09-18
ASCENT-04
Gilead Sciences
Phase 3 Active not recruiting
NCT05007106 2025-08-14
KEYVIBE-005
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT06460298 2025-08-12
ProAgio in Combination With Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer
ProDa BioTech, LLC
Phase 1/2 Recruiting
NCT02755272 2025-07-04
A Study of Pembrolizumab With Carboplatin and Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer
Fox Chase Cancer Center
Phase 2 Active not recruiting